Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics, Inc. Common Stock
(NY:
LCTX
)
1.850
+0.010 (+0.54%)
Official Closing Price
Updated: 8:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
July 02, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at 2024 BIO International Convention
May 30, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics: Q4 Earnings Insights
↗
March 07, 2024
Via
Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
↗
March 06, 2024
Via
Benzinga
Lineage Cell Therapeutics: Q3 Earnings Insights
↗
November 09, 2023
Via
Benzinga
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
May 21, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
↗
May 09, 2024
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 06, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
May 02, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Changes to Board of Directors
April 29, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
↗
March 07, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
April 30, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
April 01, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
February 29, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
March 18, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 14, 2024
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
March 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
March 11, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
February 09, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For March 7, 2024
↗
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
February 13, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
February 06, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 01, 2024
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
January 16, 2024
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
↗
January 03, 2024
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 29, 2023
Via
Benzinga
3 Penny Stocks to Buy for the Next Bull Run
↗
November 11, 2023
While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.
Via
InvestorPlace
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
December 18, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
